Kazia Therapeutics Limited
https://www.kaziatherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kazia Therapeutics Limited
Kazia Suffers Brain Cancer Drug Setback But All Hope Not Lost
News that the Australian biotech's paxalisib did not meet pre-defined criteria to continue into the second stage of a major glioblastoma platform trial saw Kazia's stock crash, but investor reaction appears to be excessive.
Tech Transfer Roundup: Sanofi Gets IP For Multiple Myeloma From Memorial Sloan Kettering
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- CanTx, Inc. (joint venture)
- Glioblast Pty Ltd
- Novogen Limited
- Triaxial Pharmaceuticals Pty Ltd